Introduction
In the mid 1990s, we isolated and characterized a peptide which we initially called daintain due to its activity of a well-sized peptide infl uencing insulin secretion (Chen et al., 1994 (Chen et al., , 1997 . According to the later investigation of this peptide, we still call it daintain which means "a well-sized infl ammatory peptide factor". At the same time, Utans et al. (1995 Utans et al. ( , 1996 identifi ed a novel macrophage factor in rat and human hearts that was undergoing chronic rejection and named it allograft infl ammatory factor-1 (AIF-1). Daintain and AIF-1 share an almost identical amino acid sequence, so we have termed the peptide daintain/AIF-1.
Daintain/AIF-1 is a 147-amino acid (16.8 kDa) cytoplasmic calcium-binding, EF-hand, interferon-gamma-inducible peptide, which is encoded within the human histocompatibility complex class III genomic region on chromosome 6p21.3 (Utans et al., 1995 (Utans et al., , 1996 Deininger et al., 2002) . Daintain/AIF-1 contains a 44-amino acid segment with the sequence pattern -KR-KK-GKR, which are structural characteristics for peptide hormone precursor proteins (Chen et al., 1997) . Daintain/AIF-1 is expressed in macrophage cell lines (Utans et al., 1996) , experimental autoimmune encephalomyelitis, neuritis and uveitis models (Schluesener et al., 1998; Pashenkov et al., 2000) , human cerebral infarctions (Postler et al., 2000) , devascularized skeletal muscles in rat systems (Kuschel et al., 2000) , and breast ductal tumour epithelia (Liu et al., 2008) . Vascular smooth muscle cells also expressed daintain/ AIF-1 when activated by cytokines or injured by balloon angioplasty ( Autieri, 1996; Autieri et al., 2000) . Microglial response factor-1 and ionized calcium-binding adapter molecule-1 are homologues of daintain/AIF-1 and have been localized to activated infi ltrating macrophages in degenerating and infl amed tissues (Tanaka et al., 1998; Imai et al., 1996; Ito et al., 1998) . Moreover, in human disease, daintain/AIF-1 is expressed by both the glandular and stromal cells in human eutopic endometrium and endometriosis (Koshiba et al., 2005) . Recent studies also indicated that daintain/ AIF-1 overexpression enhances endothelial cell Daintain/AIF-1 was identifi ed from injured rat carotid arteries and porcine intestine in the mid 1990s. It is involved in autoimmune disorders, chronic rejection of allografts, gliomas, and breast cancer. Since it is convenient and economical to obtain such a peptide biologically, in this study, we describe the expression, purifi cation, and characterization of recombinant human daintain/AIF-1 (rhdaintain/AIF-1). The backbone of vector pET32a, a high-level expression plasmid, was used to construct the pET32a-daintain/AIF-1 plasmid for daintain/AIF-1 expression in Escherichia coli. The recombinant daintain/AIF-1 protein was solubly expressed in the BL21 (DE3) strain and was purifi ed by Ni 2+ affi nity chromatography. After purifi cation, the recombinant protein showed the expected size of 18 kDa on Tricine-SDS-PAGE gels which was further confi rmed by Western blotting. A total of 34.0 mg of high purity (over 98%) rhdaintain/AIF-1 was obtained from 1 L culture. The recombinant peptide was able to increase blood glucose elimination rates and enhance the proliferation of human MCF-7 cells. These results suggest that biological activity of the recombinant peptide was preserved after purifi cation. activation, proliferation, and migration (Tian et al., 2009; Jia et al., 2010) .
Therefore, daintain/AIF-1 has been widely investigated in biology and clinical science. Unfortunately, it can currently only be obtained from porcine intestine at very low yields. This greatly limits the application of daintain/AIF-1 in various kinds of researches. To conveniently and economically obtain daintain/AIF-1, we undertook a genetic engineering approach. We optimized the cultivation parameters to express the recombinant protein in soluble form in Escherichia coli, obtaining a high yield of recombinant human daintain/AIF-1 (rhdaintain/AIF-1) after purifi cation which maintained its biological activity.
Material and Methods

Materials
The Escherichia coli strains DH5 and BL21 (DE3) and the breast cancer cell lines MCF-7 and MDA-MB-231 were purchased from China Center for Type Culture Collection (CCTCC) and were used for most routine manipulations. Plasmid pET32a was purchased from Novagen (Madison, WI, USA). T4 DNA ligase and Taq DNA polymerase were from TaKaRa Biotechnology (Kyoto, Japan). All restriction enzymes were purchased from Invitrogen (Carlsbad, CA, USA). Ni 2+ -NTA resin was obtained from GE Healthcare (Uppsala, Sweden).
Construction of pET32a-daintain/AIF-1 expression plasmid
Total RNA was isolated from MCF-7 cells following the standard protocol (Trizol, Invitrogen) and used as a template. First-strand cDNA was synthesized with a fi rst-strand synthesis kit (Invitrogen) and used for reverse transcriptionpolymerase chain reactions (RT-PCR). The following synthetic oligonucleotide primers: sense, 5 ' -G C CATAT G AT G AG C CA A AC CAG G -GATTT-3', and antisense, 5'-CACTCGAG-AATCAGGGCAACTCAGAGAT-3' (underlined sequences indicate restriction endonuclease sites), were synthesized based on the daintain/AIF-1 cDNA sequence (accession No. U19713) to amplify the daintain/AIF-1 coding region by PCR. The resulting fragment consisted of a 5'-NdeI site, the daintain/AIF-1 sequence, and a 3'-XhoI site. The DNA fragment was then cloned into the pET32a expression vector. The plasmid was used to transform the E. coli DH5 strain to generate ampicillin-resistant colonies. Clones resistant to ampicillin were selected and plasmid DNA isolated, before examination by restriction endonuclease mapping to confi rm the correct orientation of the cloned DNA. The resulting plasmid was named pET32a-daintain/AIF-1 and its structure is shown in Fig. 1 .
Rhdaintain/AIF-1 expression and purifi cation
Overnight cultures of E. coli, strain BL21 (DE3), transformed with pET32a-daintain/AIF-1 were diluted 1:100 in 1 L LB medium containing ampicillin (50 μg/mL) and incubated at 30 °C with shaking to an OD 600 of 0.6. Isopropyl--Dthiogalactopyranoside (IPTG) was then added to a fi nal concentration of 0.5 mM. After a further 3 h of growth, cells were pelleted at 6,000 × g for 10 min at 4 °C and then resuspended in 30 mL binding buffer [20 mM Na 3 PO 4 , 500 mM NaCl, 10% (v/v) glycerol, 10 mM imidazole, pH 7.4]. Cells were then sonicated and centrifuged at 18,000 × g for 20 min at 4 °C and fi ltered through a 0.45-μm pore-size fi lter. The cleared lysate was incubated in a batch with 10 mL Ni 2+ -NTA resin for 2 h at 4 °C. The resin was loaded onto a column and was thoroughly washed with binding buffer, before the bound proteins were eluted by a linear gradient of 40 -200 mM imidazole in buffer [20 mM Na 3 PO 4 , 500 mM NaCl, 10% (v/v) glycerol, pH 7.4]. Fractions containing rhdaintain/ AIF-1 were pooled and desalted with Sephadex G25 (Amersham Pharmacia Biotech AB, Uppsala, Sweden). Lyophilization was carried out after freezing fractions of Sephadex G25.
SDS-PAGE and Western blotting
Protein samples were dissociated into monomers by the addition of the nonionic detergent Triton X-100 and -mercaptoethanol, analysed using a 15% (w/v) tricine SDS-PAGE gel, and stained with Coomassie Brilliant Blue R-250 for 4 h at room temperature.
Western blotting was performed as described previously (Fu et al., 2006) . Protein samples (0.05 μg) were separated by SDS-PAGE, blotted onto a nitrocellulose membrane, and blocked for 1 h with 2% BSA (bovine serum albumin) at room temperature. After repeated washing with PBST (PBS with 0.1% Tween 20), the membranes were incubated with 1:1,000 diluted mouse monoclonal anti-daintain/AIF-1, which was prepared by our laboratory (Fu et al., 2006) , overnight at 4 °C. After repeated washing with PBST, the membranes were incubated with 1:2,000 diluted alkaline phosphatase-labeled goat anti-mouse secondary antibody (Boster, Wuhan, China) for 2 h at room temperature. The bands were visualized using the Western Blue Stabilized Substrate (Promega, Madison, WI, USA).
Determination of blood glucose levels
BALB/c mice (18 -20 g, from the Standard Animal Center of the China Medical College) were used. D-Glucose was injected intravenously (1 mg/g) into fasted BALB/c mice, alone or combined with rhdaintain/AIF-1 or combined with porcine daintain/AIF-1, at a dose of 5 μg/g (~270 nM/kg) body weight. Blood samples were taken after 1, 5, 15, 30, and 60 min. Individual blood glucose values were measured using an Accu-Chek Advantage blood glucose monitor (Roche Diagnostics, Shanghai, China). This study was approved by the institutional ethics committee of Hubei province, China.
Cell culture and proliferation assay
The human MCF-7 and MDA-MB-231 cells were maintained in DMEM medium supplemented with 10% fetal calf serum, 100 U/mL penicillin, and 100 U/mL streptomycin in a humid atmosphere of 5% CO 2 at 37 °C. For proliferation assays, equal numbers of MCF-7 cells were seeded into 24-well plates at a density of 1 · 10 4 cells per well. 1 mg of lyophilized rhdaintain/ AIF-1 was dissolved in PBS to a fi nal volume of 1 mL and stored at -20 °C after fi ltration sterilization. Rhdaintain/AIF-1 or porcine daintain at a fi nal concentration of 1 μg/mL was added to the DMEM medium, and the same volume of PBS was added as a control. Cells were cultured for 7 d with media changes on the 3rd and 5th day. After 1, 3, 5 and 7 d, viable cells were counted by trypan blue exclusion using a standard hemocytometer.
Statistical analysis
The statistical signifi cance of differential fi ndings between experimental groups and controls was determined by the Student's t-test. For all statistical analyses, signifi cance levels were set at P < 0.05.
Results
Design of pET32a-daintain/AIF-1 expression plasmid
pET32a is designed for cloning and high-level expression of peptide sequences (Lavallie et al., 1993) . If the daintain/AIF-1 coding sequence has been correctly inserted into the cloning sites of pET32a, the resulting fusion protein will contain cleavable Trx-, His-and S-Tags, and an uncleavable His-Tag. This makes the fusion protein almost twice as large as daintain/AIF-1, by molecular mass, and the protein of interest can be obtained after enterokinase cleavage and another purifi cation process. Furthermore, all the restriction sites in the multiple cloning site of pET32a will introduce some amino acid residues coded by the vector sequence to the N-terminal of the secreted rhdaintain/AIF-1. There is only a single NdeI (CATATG) restriction site in the pET32a vector. This ATG is the T7 transcription start, encoding Met, and the N-terminal of daintain/AIF-1 is also Met. Therefore, we designed two primers containing an NdeI restriction site at the 5'end and a 3'XhoI site to amplify the daintain/AIF-1 coding sequence and inserted it into the pET32a vector cleaved by the NdeI and XhoI restriction enzymes. The resulting recombinant DNA sequence therefore only contained the daintain/ AIF-1 coding sequence and the His-Tag coding sequence (Fig. 1) . This construction (pET32a-daintain/AIF-1) should produce a recombinant protein of approximately 18 kDa ( Fig. 2A) with no redundant amino acid residues attached to its N-terminal.
Expression and purifi cation of rhdaintain/AIF-1
After the induction of protein expression with IPTG, the bacteria were pelleted and sonicated, and rhdaintain/AIF-1 was identifi ed by Coomassie Blue staining. We found that the recombinant protein was almost equally distributed in the pellet and supernatant ( Fig. 2A) . To avoid the tedious denaturing and refolding process, only the supernatant of the induced bacteria cells' lysate was applied to the Ni 2+ -NTA resin. First, 20 mM imidazole was used to elute components of the supernatant that nonspecifi cally were bound to the Ni 2+ -NTA resin column. This was followed by two isocratic steps of 40 mM and 200 mM imidazole, respectively, to elute the bound protein ( Fig. 2A) . After Ni 2+ affi nity chromatography, the purity of the recombinant proteins (Fig. 2A, lane  4) reached 98%. Then, the 200 mM imidazole eluate was pooled and desalted with Sephadex G25, resulting in 34.0 mg of lyophilized rhdaintain/ AIF-1 from 1 L culture.
The purifi ed protein was assayed by Western blotting to confi rm that it was rhdaintain/AIF-1. The native daintain, which was previously purifi ed from porcine intestine (Chen et al., 1997) and the MDA-MB-231 cells, which overexpress the AIF-1 protein (Liu et al., 2008) , were used as positive controls (Fig. 2B, lanes 2 and 3) . As shown in Fig. 2B, lanes 1 -3 , the rhdaintain/AIF-1 was recognized by anti-daintain/AIF-1 antibody, just like the native daintain and AIF-1 expressed by MDA-MB-231 cells.
These results showed that E. coli BL21 (DE3) harbouring the pET32a-daintain/AIF-1 plasmid expressed the rhdaintain/AIF-1 protein, as expected.
Rhdaintain/AIF-1 increases glucose elimination rates in BALB/c mice
BALB/c mice were used to investigate whether rhdaintain/AIF-1 could infl uence the blood glucose concentration in vivo. The intravenous injection of glucose (1 mg/g) into fasted BALB/c mice rapidly raised the blood glucose levels, with a peak obtained after only 1 min, after which the blood glucose levels returned toward baseline values. The blood glucose levels measured 5 min after injection were signifi cantly lower in mice that received an injection of glucose + rhdaintain/ AIF-1 [(14.51 ± 0.19) mM, n = 8] compared to an injection of porcine daintain [(12.71 ± 0.18) mM, n = 8], and an injection of glucose alone [(19.87 ± 0.16 ) mM, n = 8], with similar results seen after 15 and 30 min (Fig. 3) . After 60 min, there was no signifi cant difference in the level of glucose between the treatment groups. This increase in glucose elimination rates following injection of rhdaintain/AIF-1 demonstrates that rhdaintain/ AIF-1 has biological activity in vivo.
Rhdaintain/AIF-1 promotes MCF-7 cell proliferation
In order to confi rm the bioactivity of rhdaintain/AIF-1 in vitro, the effect of rhdaintain/AIF-1 on the proliferation of MCF-7 cells was examined. 
Discussion
It is known that daintain/AIF-1 plays an important role in autoimmune diseases (Schluesener et al., 1998) , cancer proliferation (Liu et al., 2008) , and vasculopathy (Autieri et al., 2000) . Both basic research and potential clinical applications may require large quantities of daintain/AIF-1, but the low yields of daintain/AIF-1 obtained from natural material is one of the major restrictions in the study and application of daintain/AIF-1. To provide daintain/AIF-1 for biotechnological application, we developed a daintain/AIF-1 production method using the pET32a expression vector with a T7 promoter in E. coli.
In this study, we demonstrated that a higher dose (270 nmol/kg) of rhdaintain/AIF1 can increase blood glucose elimination rates in BALB/c mice as in our previous report (Chen et al., 1997) , but lower doses (27 nmol/kg and 2.7 nmol/kg) of rhdaintain/AIF-1 had no effect (data not shown). This might be so because the specifi c activity of the recombinant protein was lower than that of the native protein, or the dose subdivisions were too extended, or the mice strains differed in their responsiveness. Nevertheless, our results show that rhdaintain/AIF-1 has biological activity in vivo. It has been reported that daintain/AIF-1 can promote the proliferation of vascular smooth muscle cells (Autieri et al., 2000) , T lymphocytes (Kelemen and Autieri, 2005) , macrophages (Tian et al., 2006) , human vascular endothelial cells (Tian et al., 2009) , and another breast cancer cell line, MDA-MB-231 (Liu et al., 2008) . These reports demonstrated that overexpression of intracellular daintain/AIF-1 by transfection can promote cell proliferation. However, it has not yet been reported whether extracellular daintain/ AIF-1 has effects on cell proliferation. In the Fig. 3 . Rhdaintain/AIF-1 increases blood glucose elimination rates. Blood glucose levels after an intravenous injection of glucose (1 mg/g) with or without the peptides rhdaintain/AIF-1 and porcine daintain (5 μg/g) were measured after 1, 5, 15, 30, and 60 min. BALB/c mice were used in each group (n = 8), and there has been signifi cant difference between injection with the peptides and negative control, P < 0.05; error bars show means ± SD.
Blood glucose level [mM]
Time [min] Fig. 4 . Rhdaintain/AIF-1 enhances MCF-7 proliferation. Equal numbers of pooled MCF-7 cells were seeded into 24-well plates. The experimental groups received 1 μg/ mL rhdaintain/AIF-1 and 1 μg/mL porcine daintain, respectively, another equal volume of PBS was added as a control. After 1, 3, 5, and 7 d, viable cells were counted by trypan blue exclusion in triplicate. Data represent at least three independent experiments (between experimental group and control, P < 0.05; error bars show means ± SD). present study, we added rhdaintain/AIF-1 into culture medium and found that it is conducive to MCF-7 cell proliferation. To our knowledge, this is the fi rst report describing the promotion of cell proliferation through the application of high levels of extracellular daintain/AIF-1. This result indicates that the actions of rhdaintain/AIF-1 in vitro are similar to the actions observed when daintain/AIF-1 is overexpressed and the activity of rhdaintain/AIF-1 in vitro is preserved after purifi cation.
In summary, we have succeeded in expressing and purifying the rhdaintain/AIF-1 protein without redundant amino acid residues attached to its N-terminal by biological engineering. The purification of rhdaintain/AIF-1 protein was confi rmed by Western blotting. We further demonstrated that rhdaintain/AIF-1 has biological activities in vivo and in vitro. Thus, the present study provides us with a useful tool to obtain large amounts of functional rhdaintain/AIF-1 protein, which could be utilized as a highly purifi ed biological reagent for structural, biochemical, biological, and clinical investigations.
